Phase I, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors, including Pancreatic Cancer
The purpose of this phase I/II study is to evaluate the safety and tolerability of TH1902 in patients with solid tumors, including pancreatic cancer.
Study ID: TH1902-CTR-0001
Trial Phase: Phase I
Trial Sponsor: Theratechnologies
Therapies Used in This Trial: TH1902 peptide-drug conjugate